

Ren-ai Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6337932/publications.pdf>

Version: 2024-02-01

48
papers

559
citations

687220

13
h-index

713332

21
g-index

48
all docs

48
docs citations

48
times ranked

597
citing authors

#	ARTICLE	IF	CITATIONS
1	UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 166, 6-12.	1.4	64
2	Simvastatin prevents and ameliorates depressive behaviors via neuroinflammatory regulation in mice. <i>Journal of Affective Disorders</i> , 2019, 245, 939-949.	2.0	45
3	Structure-activity relationships of phthalates in inhibition of human placental 3 β -hydroxysteroid dehydrogenase 1 and aromatase. <i>Reproductive Toxicology</i> , 2016, 61, 151-161.	1.3	34
4	Effects of hydroxysafflor yellow A on the activity and mRNA expression of four CYP isozymes in rats. <i>Journal of Ethnopharmacology</i> , 2014, 151, 1141-1146.	2.0	33
5	Effects of aescin on cytochrome P450 enzymes in rats. <i>Journal of Ethnopharmacology</i> , 2014, 151, 583-590.	2.0	32
6	Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3503-3510.	2.0	32
7	Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by ultra high performance liquid chromatography tandem mass spectrometry and its application to a bioequivalence study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 957, 110-115.	1.2	30
8	In vivo Pharmacokinetic Drug-Drug Interaction Studies Between Fedratinib and Antifungal Agents Based on a Newly Developed and Validated UPLC/MS-MS Method. <i>Frontiers in Pharmacology</i> , 2020, 11, 626897.	1.6	27
9	Functional Characterization of 22 <sc>CYP</sc>3A4 Protein Variants to Metabolize Ibrutinib <i>In Vitro</i>. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 383-387.	1.2	21
10	UPLC-MS/MS method for the quantification of ertugliflozin and sitagliptin in rat plasma. <i>Analytical Biochemistry</i> , 2019, 567, 112-116.	1.1	18
11	Simultaneous determination of bosentan and glimepiride in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 95, 207-212.	1.4	15
12	Simultaneous determination of liensinine, isoliensinine and neferine in rat plasma by UPLC-MS/MS and application of the technique to pharmacokinetic studies. <i>Journal of Ethnopharmacology</i> , 2015, 163, 94-98.	2.0	13
13	Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. <i>OncoTargets and Therapy</i> , 2016, 9, 2421.	1.0	13
14	The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 2129-2135.	1.1	13
15	Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 187, 113355.	1.4	12
16	Inhibitory effects of voriconazole, itraconazole and fluconazole on the pharmacokinetic profiles of ivosidenib in rats by UHPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 187, 113353.	1.4	12
17	Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC-MS/MS assay. <i>Pharmaceutical Biology</i> , 2022, 60, 621-626.	1.3	12
18	Anti-Lung Cancer Activity of the Curcumin Analog JZ534 In Vitro. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	11

#	ARTICLE	IF	CITATIONS
19	Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro. <i>Chemical Research in Toxicology</i> , 2019, 32, 1583-1590.	1.7	11
20	Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 513-519.	2.0	10
21	Development of UPLC-MS/MS method for studying the pharmacokinetic interactions of pexidartinib with antifungal drugs in rats. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 188, 113386.	1.4	10
22	Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1909.	2.0	9
23	Functional characteristics of CYP3A4 allelic variants on the metabolism of loperamide in vitro. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 2809-2817.	1.1	7
24	Drug-drug interaction study of imatinib and voriconazole in vitro and in vivo. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1021-1027.	1.1	6
25	Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 190, 113496.	1.4	6
26	TA allele of rs2070673 in the <i>CYP2E1</i> gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2925-2934.	1.4	6
27	Analytical methodology and pharmacokinetic study of elagolix in plasma of rats using a newly developed UPLC-MS/MS assay. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103235.	2.3	5
28	Effects of salidroside on rat CYP enzymes by a cocktail of probe drugs. <i>Iranian Journal of Basic Medical Sciences</i> , 2018, 21, 422-426.	1.0	5
29	Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine. <i>Drug Design, Development and Therapy</i> , 2016, 10, 687.	2.0	4
30	Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro. <i>Fundamental and Clinical Pharmacology</i> , 2021, , .	1.0	4
31	Development of a Prognostic Five-Gene Signature for Diffuse Lower-Grade Glioma Patients. <i>Frontiers in Neurology</i> , 2021, 12, 633390.	1.1	4
32	A novel bioanalytical method for the quantification of pemigatinib in rat plasma by UPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 202, 114137.	1.4	4
33	Determination and Pharmacokinetic Profiles of Four Active Components From <i>Scrophularia ningpoensis</i> Hemsl. in Rats. <i>Frontiers in Pharmacology</i> , 2020, 11, 612534.	1.6	4
34	Characterization of Alpelisib in Rat Plasma by a Newly Developed UPLC-MS/MS Method: Application to a Drug-Drug Interaction Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 743411.	1.6	4
35	The changes of expressive levels of IL-17A, STAT3, and ROR γ t in different invasive pulmonary aspergillosis mice. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1321-1328.	1.1	3
36	A Novel UPLC-MS/MS Assay for the Measurement of Linezolid and its Metabolite PNU-142300 in Human Serum and its Application to Patients With Renal Insufficiency. <i>Frontiers in Pharmacology</i> , 2021, 12, 641872.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Development and validation of the quantitative determination of avapritinib in rat plasma by a bioanalytical method of UPLC-MS/MS. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103152.	2.3	3
38	Evaluation of herb-drug interaction of ambrisentan with shikonin based on UPLC-MS/MS. <i>Pharmaceutical Biology</i> , 2021, 59, 1131-1136.	1.3	3
39	UPLC-MS/MS for simultaneous quantification of vortioxetine and its metabolite Lu AA34443 in rat plasma and its application to drug interactions. <i>Arabian Journal of Chemistry</i> , 2020, 13, 8218-8225.	2.3	2
40	Inhibitory effect of propafenone on vortioxetine metabolism in vitro and in vivo. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103136.	2.3	2
41	Effects of 31 recombinant CYP2C19 variants on clomipramine metabolism in vitro. <i>Journal of Psychopharmacology</i> , 2021, 35, 1517-1522.	2.0	2
42	Evaluation of CYP2C9 Activity in Rats: Use of Tolbutamide Alone and in Combined with Bupropion. <i>Iranian Journal of Pharmaceutical Research</i> , 2014, 13, 635-9.	0.3	2
43	Identification and Enzymatic Activity Evaluation of a Novel CYP2C9 Allelic Variant Discovered in a Patient. <i>Frontiers in Pharmacology</i> , 2021, 12, 619339.	1.6	1
44	Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles. <i>Pharmaceutical Biology</i> , 2022, 60, 1-8.	1.3	1
45	Effect of Sophocarpine on the Pharmacokinetics of Umbrisib in Rat Plasma Using a Novel UPLC-MS/MS Method. <i>Frontiers in Pharmacology</i> , 2022, 13, 749095.	1.6	1
46	Inhibitory effect of sesamin on ivabradine metabolism in rats. <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2020, 33, 2543-2546.	0.2	0
47	Effect of Baicalein on the Pharmacokinetics of Cilostazol and Its Two Metabolites in Rat Plasma Using UPLC-MS/MS Method. <i>Frontiers in Pharmacology</i> , 2022, 13, 888054.	1.6	0
48	UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0